Business
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced it will host a conference call and webcast to present 3-year data from the long-term follow
About this update from Meiragtx Holdings Plc
[{"type":"image","alt":"MeiraGTx","displaySize":"","headline":null,"caption":"MeiraGTx","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/60ece5081b9af642a0dc8da28326e24c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eC4lbfkMlXttl7mRddmcYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgz/https://media.zenfs.com/en/globenewswire.com/60ece5081b9af642a0dc8da28326e24c","width":300,"height":59}},"lazy":false},{"type":"text","content":"- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study","length":90,"tagName":"p"},{"type":"text","content":"- Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures.","length":140,"tagName":"p"},{"type":"text","content":"LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced it will host a conference call and webcast to present 3-year data from the long-term follow-up of patients in the Phase 1 study of AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX) on Thursday, April 16, 2026, at 8:00 a.m. ET.","length":469,"tagName":"p"},{"type":"text","content":"The presentation will include:","length":30,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Three-year data from the long-term follow-up of the patients in the open-label Phase 1 AQUAx clinical study.This data will include:","length":133,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"PRO Xerostomia Questionnaire (XQ) data out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Objective Unstimulated Whole Saliva Flow Rate (UWSFR) data out to 3 years","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Full cohort data, as well as individual patient data out to 3 years for both the XQ and UWSFR","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":291,"olType":false}]},{"val":[{"type":"text","content":"Study Investigator discussion of disease burden, patient experience, and treatment administration","length":97,"tagName"...